百瑞吉首发获北交所上市委会议通过

Core Viewpoint - Changzhou Baijie Biological Medicine Co., Ltd. has received approval for its initial public offering (IPO) on the Beijing Stock Exchange, focusing on the development, production, and sales of biomedical materials [2] Financial Performance - The company reported revenues of 151 million yuan, 198 million yuan, and 231 million yuan for the years 2022, 2023, and 2024 respectively, indicating a revenue growth of 16.68% in 2024 [2] - Net profits for the same years were 31.06 million yuan, 50.08 million yuan, and 52.31 million yuan, showing a year-on-year increase of 4.46% in 2024 [2] Key Financial Metrics - Revenue for 2024 is projected at 231.23 million yuan, up from 198.18 million yuan in 2023 and 150.74 million yuan in 2022 [2] - Net profit attributable to shareholders for 2024 is expected to be 52.31 million yuan, compared to 50.08 million yuan in 2023 and 31.06 million yuan in 2022 [2] - Basic earnings per share for 2024 is forecasted at 0.87 yuan, consistent with 0.83 yuan in 2023 and down from 0.94 yuan in 2022 [2] - The weighted average return on equity for 2024 is projected at 24.33%, down from 29.81% in 2023 and 27.11% in 2022 [2] - The net cash flow from operating activities for 2024 is expected to be 67.89 million yuan, an increase from 59.71 million yuan in 2023 and 27.78 million yuan in 2022 [2]